MIT Non-Pegylated Lipid Nanoparticles, Therapeutic Applications
Summary
Massachusetts Institute of Technology published patent application US20260108622A1 on April 23, 2026, claiming non-PEGylated lipid nanoparticles comprising an outer polyanionic layer, compositions thereof, and methods of using said particles for therapeutic applications. The application (No. 19364970) has a priority filing date of October 21, 2025, and covers CPC classifications including A61K 47/6911, A61K 9/0019, A61K 31/7105, and related pharmaceutical categories. Inventors include Paula T. Hammond-Cunningham, Namita Rajesh Nabar, and Deeksha Kumaresh.
“Provided herein are non-PEGylated lipid nanoparticles comprising an outer polyanionic layer, compositions thereof, and methods of using said particles or compositions for therapeutic applications.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
MIT published patent application US20260108622A1 disclosing non-PEGylated lipid nanoparticles with an outer polyanionic layer, compositions thereof, and methods of using said particles for therapeutic applications. The invention is classified under multiple CPC codes including A61K 47/6911, A61K 9/0019, A61K 31/7105, A61K 47/58, A61K 47/61, A61K 47/62, A61K 48/0033, A61K 48/0083, C12N 15/88. The application has a priority filing date of October 21, 2025, and was published April 23, 2026.
This publication has no immediate compliance implications for third parties. Competitors developing nucleic acid delivery systems using lipid nanoparticles may wish to review the claims for potential freedom-to-operate concerns once the application proceeds to grant.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
NON-PEGYLATED LIPID NANOPARTICLES
Application US20260108622A1 Kind: A1 Apr 23, 2026
Assignee
Massachusetts Institute of Technology
Inventors
Paula T. Hammond-Cunningham, Namita Rajesh Nabar, Deeksha Kumaresh
Abstract
Provided herein are non-PEGylated lipid nanoparticles comprising an outer polyanionic layer, compositions thereof, and methods of using said particles or compositions for therapeutic applications.
CPC Classifications
A61K 47/6911 A61K 9/0019 A61K 31/7105 A61K 47/58 A61K 47/61 A61K 47/62 A61K 48/0033 A61K 48/0083 C12N 15/88
Filing Date
2025-10-21
Application No.
19364970
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.